Fluicell
Develops high-resolution single-cell bioprinters (Biopixlar®) for tissue engineering and drug development, enabling precise 3D tissue fabrication without bioink.
- CEO / Founder
- Carolina Trkulja
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $600K
- Latest Round
- Grant
- Key Investors
- Avanza Pension, Viola Vitalis AB, Nordnet Pensionsförsäkrning, Niklas Frisk, Thomas Claes Alarik Alander, Gökhan Ziyanak, Andreas Holmström, Krister Hultberg, Magnus Folkesson, Björn Hörlin
Technology & Products
Key Products
Biopixlar (modular research platform for single cell arrays, organoids, and complex tissues), BioPen, Dynaflow Resolve, Biopixlar AER (compact 3D bioprinter).
Technological Advantage
Proprietary open-volume microfluidics technology achieves >95% cell viability and single-cell precision, protected by 5 patent families; first commercial microfluidics-based high-resolution bioprinter without bioink.
Differentiation
Value Proposition
Reduces tissue model development time from months to days with single-cell precision (>95% viability), enabling faster drug screening and personalized medicine at lower cost per assay.
How They Differentiate
3x higher cell viability (>95% vs ~80% for conventional bioprinters) and single-cell resolution without bioink, unlike competitors relying on bioink-based extrusion; Biopixlar AER is 50% more compact than standard bioprinters for lab integration.
Market & Competition
Target Customers
Pharmaceutical companies, academic research labs, biotech firms
Industry Verticals
Pharmaceuticals; Biotechnology; Academic Research; Regenerative Medicine
Competitors
Organovo, Advanced Solutions, Allevi, CELLINK
Growth & Milestones
Growth Metrics
Installed base of Biopixlar systems at 10+ research institutions globally; 2023 revenue SEK 8.9 million (approximately $850,000 USD); 2022 revenue SEK 6.8 million (approximately $650,000 USD) representing 31% year-over-year growth
Major Milestones
Launched Biopixlar® AER in Q1 2022; Signed first beta testing agreement with Cellectricon AB; Developed Nexocyte™ platform for tissue-based therapeutics
Notable Customers
Dr. Luiz Bertassoni, Director Knight Cancer Precision Biofabrication Hub; Dr. Dani Cai, National Institute of Health; Prof. Megan Rizzo, University of Maryland Medical Center; Dr. Veronica Jove, Rockefeller University; Dr. Timm Danker, NMI TT